Ashish Nimgaonkarand: Ledger

Stories naming Ashish Nimgaonkarand. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Role	Organisation	Sources
Chief Executive	Glyscend	Brandon BioCatalyst portfolio

Unnamed stage $29m

Adelaide Type 2 Diabetes researchers zero in on an 'operation in a pill'

Glyscend Therapeutics, an Adelaide-Baltimore biotech, is recruiting volunteers for phase 1 trials of GLY-200, a pill mimicking gastric bypass for type 2 diabetes, developed with $29 million from MRCF, Santé Ventures and Breakout Labs.

Brandon BioCatalyst portfolio Tue 3 Aug 2021 Glyscend Brandon Capital CMAX PayPal Royal Adelaide Hospital University of Adelaide Breakout Labs Medical Research Commercialisation Fund (MRCF)Santé Ventures Ashish Nimgaonkarand Professor Chris Rayner Peter Thiel

Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio

Ashish Nimgaonkarand

Roles

Coverage

Adelaide Type 2 Diabetes researchers zero in on an 'operation in a pill'